Introduction: Bromocriptine, an ergot derivative, is an agonist at the dopamine 2 receptor and a sympatholytic. It is a well established drug in Parkinsonism, hyperprolactinaemia and acromegaly and it has various other clinical indications like induction of ovulation in female infertility. Bromocriptine has been evaluated in alloxan induced diabetic rats for its antihyperglycaemic effect with and without simultaneous use of glipizide.
INTRODUCTION
Diabetes is an "iceberg" disease. The increasing worldwide incidence of Diabetes Mellitus (DM) in adults is a global public health burden. Diabetes mellitus is a group of heterogenous disorders in which carbohydrate metabolism is reduced, while those of proteins and lipids are increased. Hyperglycaemia is a common end point for all types of DM and it is an important parameter which can be assessed to evaluate the effectiveness of anti-diabetic drugs. The goals of therapy for diabetes are to alleviate the symptoms which are related to hyperglycaemia and to prevent or reduce the acute and chronic complications of diabetes. Because of its multi-factorial pathogenesis, restoration of normoglycaemia is difficult to achieve and it requires multiple anti-diabetic medications in combination, to produce an additive effect. Therefore, the development of antidiabetic agents that have novel mechanisms of action and can be used in combination with currently approved medications for the treatment of type 2 Diabetes mellitus, is highly desirable.
The idea of using bromocriptine for the treatment of type-2 diabetes came while the metabolism of migratory birds was studied, in which they develop seasonal insulin resistance and dopamine plays a role in it [1] . This dopamine agonist is thought to potentially decrease insulin resistance and hepatic glucose production through an increase in dopaminergic neurotransmission, which can reset the hypothalamus and improve insulin sensitivity [2] . As dopaminergic activity is also related to the food intake and energy expenditure [3] , it is thought that this dopamine receptor agonist plays a role in bringing down hyperglycaemia. Hence, the present study was undertaken to explore the possible anti-hyperglycaemic action of bromocriptine, which may be an addition to its therapeutic utility. Our objectives were as follows:
• To study the anti-hyperglycaemic activity of bromocriptine.
• To compare its anti-hyperglycaemic activity with that of glipizide, which is an established anti-diabetic drug.
• To study the anti-hyperglycaemic activity of sub therapeutic doses of bomocriptine and glipizide in combination.
MATERIAL AND METHODS
A. animals: Albino rats which were 12 weeks old, which were of either sex, which weighed 150-200 grams, were bred locally in central animal house of S.S.I.M.S and R.C, Davanagere, Karnataka, India, and were used in the study. This study was approved by the institutional animal ethical committee of S.S.I.M.S and R.C., Davangere. The animals were housed in polypropylene cages and they were maintained under standard laboratory conditions at an ambient temperature of 23±2 º C, with 12 hour light/12 hour dark cycles. Rats were fed with pellet chow diet and water ad libitum. a. induction of diabetes: Albino rats of either sex were injected with alloxan in a dose of 150 mg/kg body weight. Alloxan was freshly dissolved in sterile normal saline and it was administered subcutaneously [4, 5] . Animals were treated with 10% dextrose orally, to combat the early phase of hypoglycaemia [6] . After 72 hours of alloxan treatment, the rats which showed blood glucose levels of 350mg/dl and above were included in the study and they were divided into four groups of six animals each. and 24 th hour after the drug administration on each of those particular days [10] . Blood sugar level was estimated by using a glucometer.
StatiStiCal analySiS
The results were expressed in Mean ± SD and they were analyzed by repeated measures ANOVA test. The effects of bromocriptine alone and of its combination with glipizide were compared with the anti-diabetic activity of glipizide.
RESULTS
As per [Table/ Fig-1 and 2 ]:
Group1 which was treated with distilled water served as negative control, wherein there was no marked variation in the blood sugar levels during the study period of 30 days, though slight alterations which lacked statistical significance were observed. Group 2, a standard group, served as a positive control, which was treated with glipizide 2.5 mg/kg body wt, which showed a gradual reduction in the blood glucose levels in the span of 30 days of treatment. The blood glucose level which was 387.3 mg/dl before the start of experiment decreased up to 154.3 mg/dl at the end of 30 th day, which implied a high statistical significance (p<0.001).
As per [ [Table/ Fig-2 ]: Blood glucose levels seen in control group at fixed time intervals on the days of blood glucose estimation gradual reduction in the blood sugar levels until 6 th hour observations on the respective days of blood sugar estimation. There was a marked fall in the blood glucose level from 388.5 mg/dl on 0 th day to 254.8 mg/dl on 30 th day. The results, though they were statistically highly significant, (p<0.001) were not on par with the results which were obtained in case of Group 2.
As per [Table/Fig-7 and 8]:
Group 4 which was treated with a combination of sub therapeutic doses of bromocriptine 2 mg/kg body wt and glipizide 1.25 mg/ kg body wt, showed highly significant statistics in the fall in blood glucose levels (p<0.001). There was a gradual and a sustained reduction in the blood sugar level, which fell from being 385.7 mg/ dl on 0 th day to 180.2 mg/dl on 30 th day. These observations are quiet comparable with the results of glipizide 2.5 mg/kg body wt treated group.
DISCUSSION
The results indicated that bromocriptine reduced the blood sugar level gradually for a limited period of time and that the reduction would become more prominent on repeated use. The efficacy of bromocriptine alone (4 mg/kg body wt) was not comparable to that of the standard drug glipizide (2.5 mg/kg body wt), but the combination of sub-therapeutic doses of Glipizide 1.25 mg/kg body wt and bromocriptine 2 mg/kg body wt produced an additive effect which was definitely comparable to therapeutic dose of glipizide. Another point which had to be noted was that there was no evidence of any drastic increase in blood sugar levels at any point inducing ovulation [20] . From this study, we can focus on its possible synergistic anti-hyperglycaemic effect with other established antidiabetic agents like glipizide, in doses which are below normal therapeutic range. of time during the experimentation, which indicated their persistent anti-hyperglycaemic effects.
CONCLUSION
Bromocriptine is unique in that it does not have a specific receptor that mediates its action on glucose and lipid metabolism. Rather, its effects are mediated via resetting of dopaminergic and sympathetic tones within the CNS [11] . There is a large unmet need for new therapies for treating type 2 DM, which reduces fasting and postprandial glucose without increasing insulin levels and which are not associated with weight gain or hypoglycaemia. The quick release formulation of bromocriptine (Cycloset) represents such a therapy [12] . It can thus be specifically indicated as an adjunct to diet and exercise for improving glycaemic control. Type 2 diabetic patients are at a high risk for atherosclerotic CVS complications. There have been reports which have shown beneficial effects of bromocriptine usage in hypertension [13] , obesity [14] and dyslipidaemia [15] , which in-turn were cause and effect of diabetes. Therefore, bromocriptine can be counted as an anti-diabetic agent that not only improves glycaemia but also provides overall safety in cardiovascular outcomes [16] .
The mechanism of action of this agent is unclear; however, its activity as a dopamine D 2 receptor agonist seems to provide the primary mechanism for utility in resetting the Circadian rhythm in patients with type 2 DM. Other mechanisms which include an α-1 antagonist, an α-2 agonist and serotonin and prolactin modulators, may also help in explaining bromocriptine's glucose-lowering effects [17] . The observations of our study showed a definite antihyperglycaemic effect with Bromocriptine.
Bromocriptine is known to be associated with nasal stuffiness, nausea, headache, constrictive pericarditis, neuroleptic malignant syndrome and hypotension [18] as various side effects in humans.
Owing to its proposed usage in sub-therapeutic doses due to its anti-diabetic effect, it is thought to produce lesser side effects relatively. However, long term follow ups are required. Further evaluator studies are required to strengthen its safety profile, before implying its wider usage in humans.
Bromocriptine is an important drug which is used in parkinsonism, hyperprolactinaemia and acromegaly [19] , and it is also effective in Bromocriptine produces a considerable reduction in the blood glucose but the response with sub-therapeutic doses of combination of bromocriptine and glipizide is quite encouraging. This may reduce the need of full therapeutic doses of individual drugs, thereby reducing the adverse effects and cost of medication.
Further clinical trials are required to confirm the above observations. If this is proved beyond doubt, then bromocriptine may become an additional boon for diabetic patients.
